CO6160333A2 - Bacterinas tratadas con calor y vacunas de emulsion preparadas a partir de estas bacterinas tratadas con calor - Google Patents

Bacterinas tratadas con calor y vacunas de emulsion preparadas a partir de estas bacterinas tratadas con calor

Info

Publication number
CO6160333A2
CO6160333A2 CO09024344A CO09024344A CO6160333A2 CO 6160333 A2 CO6160333 A2 CO 6160333A2 CO 09024344 A CO09024344 A CO 09024344A CO 09024344 A CO09024344 A CO 09024344A CO 6160333 A2 CO6160333 A2 CO 6160333A2
Authority
CO
Colombia
Prior art keywords
bacterin
heat
heat treated
lipase activity
leptospira
Prior art date
Application number
CO09024344A
Other languages
English (en)
Inventor
Mark D Goodyear
Nancee Lois Oien
Michael John Hueher
Ramasamy Mannar Mannan
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of CO6160333A2 publication Critical patent/CO6160333A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/0225Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55577Saponins; Quil A; QS21; ISCOMS
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

1.- Una bacterina tratada con calor, que comprende una suspensión de bacterias muertas que tienen una actividad lipasa de 50% o menos con respecto a la actividad lipasa de la bacterina antes del tratamiento con calor. 2.- Una bacterina tratada con calor de acuerdo con la reivindicación 1, donde e! tratamiento con calor comprende calentar una bacterina que tiene actividad lipasa a una temperatura de aproximadamente 35 a aproximadamente 80°C durante un periodo de aproximadamente 20 minutos a aproximadamente 24 horas. 3.- Una bacterina tratada con calor de acuerdo con la reivindicación 1, donde el tratamiento con calor comprende calentar una bacterina que tiene actividad lipasa a una temperatura de aproximadamente 60 a aproximadamente 70°C durante un periodo de aproximadamente 5 a aproximadamente 10 horas. 4.- Una bacterina tratada con calor de acuerdo con la reivindicación 1, donde el tratamiento con calor comprende calentar una bacterina que tiene actividad lipasa a una temperatura de aproximadamente 65 a aproximadamente 70°C durante un periodo de aproximadamente 9 a aproximadamente 8 horas. 5.- Una bacterina tratada con calor que comprende una suspensión de bacterias muertas de acuerdo con la reivindicación 1, donde el tratamiento con calor comprende: calentar una bacterina que tiene actividad lipasa a una temperatura de aproximadamente 65 a aproximadamente 70°C durante aproximadamente 1 hora. 6.- Una bacterina tratada con calor que comprende una suspensión de bacterias muertas de acuerdo con la reivindicación 1, donde el tratamiento con calor comprende: calentar una bacterina que tiene actividad lipasa a una temperatura de aproximadamente 55 a aproximadamente 65°C durante un periodo de aproximadamente 5 a aproximadamente 8 horas. 7.- Una bacterina tratada con calor que comprende una suspensión de bacterias muertas de acuerdo con la reivindicación 2, donde las bacterias muertas son de una a cinco especies de Leptospira seleccionadas entre el grupo compuesto por Leptospira canicola, Leptospira grippotyposa, Leptospira hardjo, Leptospira icterohaemorrhagiae y Leptospira pomona.8.- Una vacuna que comprende una emulsión y una bacterina tratada con calor de acuerdo con la reivindicación 2. 9.- Una vacuna de acuerdo con la reivindicación 8, que comprende además virus vivos.
CO09024344A 2006-09-11 2009-03-10 Bacterinas tratadas con calor y vacunas de emulsion preparadas a partir de estas bacterinas tratadas con calor CO6160333A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84366506P 2006-09-11 2006-09-11

Publications (1)

Publication Number Publication Date
CO6160333A2 true CO6160333A2 (es) 2010-05-20

Family

ID=39110574

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09024344A CO6160333A2 (es) 2006-09-11 2009-03-10 Bacterinas tratadas con calor y vacunas de emulsion preparadas a partir de estas bacterinas tratadas con calor

Country Status (27)

Country Link
US (1) US8491915B2 (es)
EP (2) EP2066340B1 (es)
JP (2) JP5550341B2 (es)
KR (1) KR101238486B1 (es)
CN (1) CN101516393B (es)
AR (1) AR062758A1 (es)
AU (1) AU2007297287B2 (es)
BR (1) BRPI0716548B1 (es)
CA (1) CA2663166C (es)
CL (1) CL2007002621A1 (es)
CO (1) CO6160333A2 (es)
DK (2) DK2377550T3 (es)
ES (2) ES2432392T3 (es)
HK (1) HK1130202A1 (es)
ME (1) ME00598B (es)
MX (1) MX2009001849A (es)
NO (1) NO339147B1 (es)
NZ (2) NZ595748A (es)
PL (2) PL2066340T3 (es)
PT (1) PT2066340E (es)
RS (1) RS54981B1 (es)
RU (2) RU2425692C2 (es)
SI (1) SI2066340T1 (es)
TW (1) TWI361077B (es)
UA (1) UA98115C2 (es)
WO (1) WO2008032158A2 (es)
ZA (1) ZA200902493B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ585877A (en) * 2007-12-21 2012-06-29 Pfizer Heat treated bacterins, and emulsion vaccines prepared from such heat treated bacterins
EP2717055A1 (en) * 2012-10-04 2014-04-09 Institut Pasteur Use of Leptospira fainei serovar Hurstbridge bacteria for diagnosing leptospirosis
AU2020450947A1 (en) * 2020-05-26 2023-02-02 Cyrus 21St Century Entrpreneurship Llc Hakim pour cina's gand zoda-e

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3721169A1 (de) * 1986-06-30 1988-01-14 Lion Corp Orale zubereitung
US5084269A (en) 1986-11-06 1992-01-28 Kullenberg Fred W Adjuvant for dose treatment with antigens
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
AU2001234616A1 (en) 2000-01-31 2001-08-07 Vic Jira Vaccine composition, process and methods
US20030147914A1 (en) 2001-07-02 2003-08-07 Pfizer Inc. Mycoplasma bovis vaccine and methods of reducing pneumonia in animals
ME00810B (me) 2002-08-26 2012-03-20 Zoetis Services Llc Vakcina za infekcije respiratornog i reproduktivnog sistema kod stoke
EP1549135A4 (en) 2002-09-20 2006-01-11 Us Agriculture VACCINE AND ADJUVANT COMPOSITIONS
AU2002951692A0 (en) 2002-09-23 2002-10-17 Vital Biotech (Hong Kong) Limited Improvements in or relating to vaccines
PL378001A1 (pl) * 2003-01-29 2006-02-20 Pfizer Products Inc. Szczepionki przeciw Bordetella bronchiseptica dla psów
WO2004087204A2 (en) * 2003-04-04 2004-10-14 Pfizer Products Inc. Microfluidized oil-in-water emulsions and vaccine compositions

Also Published As

Publication number Publication date
CL2007002621A1 (es) 2008-03-14
MX2009001849A (es) 2009-03-02
NO20090745L (no) 2009-03-11
NZ574896A (en) 2011-11-25
AU2007297287B2 (en) 2013-03-14
JP2010502238A (ja) 2010-01-28
BRPI0716548B1 (pt) 2020-10-06
RU2569457C2 (ru) 2015-11-27
CN101516393B (zh) 2014-05-14
RU2011115400A (ru) 2012-10-27
EP2377550B1 (en) 2015-03-04
JP5643906B2 (ja) 2014-12-17
RU2425692C2 (ru) 2011-08-10
BRPI0716548A2 (pt) 2013-09-24
RU2009108004A (ru) 2010-10-20
PL2066340T3 (pl) 2013-12-31
DK2066340T3 (da) 2013-10-14
WO2008032158A2 (en) 2008-03-20
US20080112970A1 (en) 2008-05-15
EP2066340B1 (en) 2013-07-31
TWI361077B (en) 2012-04-01
MEP7509A (en) 2011-12-20
DK2377550T3 (en) 2015-04-07
ES2535977T3 (es) 2015-05-19
ME00598B (me) 2011-12-20
SI2066340T1 (sl) 2013-11-29
CA2663166C (en) 2015-11-03
AR062758A1 (es) 2008-12-03
ZA200902493B (en) 2010-03-31
EP2066340A2 (en) 2009-06-10
UA98115C2 (ru) 2012-04-25
EP2377550A1 (en) 2011-10-19
PL2377550T3 (pl) 2015-07-31
NO339147B1 (no) 2016-11-14
CN101516393A (zh) 2009-08-26
RS20090088A (en) 2010-06-30
PT2066340E (pt) 2013-10-30
HK1130202A1 (en) 2009-12-24
ES2432392T3 (es) 2013-12-03
JP2014088428A (ja) 2014-05-15
AU2007297287A1 (en) 2008-03-20
WO2008032158A3 (en) 2008-07-03
US8491915B2 (en) 2013-07-23
RS54981B1 (sr) 2016-11-30
KR101238486B1 (ko) 2013-03-04
CA2663166A1 (en) 2008-03-20
TW200820990A (en) 2008-05-16
NZ595748A (en) 2013-07-26
JP5550341B2 (ja) 2014-07-16
KR20090039840A (ko) 2009-04-22

Similar Documents

Publication Publication Date Title
RU2015109724A (ru) Жидкие стабильные вирусные вакцины
IN2014DN08830A (es)
TW200719912A (en) Porcine circovirus and helicobacter combination vaccines and methods of use
CO6260102A2 (es) Cepas de mycoplasma gallisepticum atenuadas
AR075484A1 (es) Pestivirus quimericos
AR043892A1 (es) Metodos para prevenir enfermedades reproductivas en el ganado vacuno
CO6160333A2 (es) Bacterinas tratadas con calor y vacunas de emulsion preparadas a partir de estas bacterinas tratadas con calor
WO2009077577A3 (en) Vaccine antigens from piscirickettsia salmonis
DE602004028029D1 (en) Rwendung
Altaf et al. Antibody response of rabbits to combined hemorrhagic septicemia and foot & mouth disease virus vaccine.
RU2015109124A (ru) Иммуногенная композиция из убитой бактерии лептоспиры
Aiswarya et al. Characterization of Pasteurella multocida isolates of buffalo origin from Gujarat state of India by outer membrane protein profile analysis
CY1113061T1 (el) Ανοσογονες συνθεσεις για θεραπεια και προληψη ζωικων μολυνσεων
WO2008121487A3 (en) Live attenuated virus vaccines for la crosse virus and other bunyaviridae
RU2013135887A (ru) Композиции для комплекса респираторных заболеваний собак
US20220213448A1 (en) Viral vaccines and methods of forming the same
US11286464B2 (en) Viral vaccines and methods of forming the same
RU2013126074A (ru) Вакцина против чумы, аденовирусных инфекций, парвовирусного и коронавирусного энтеритов, лептоспироза и бешенства собак
Arshad et al. Experimental Trials of Foot-and-Mouth Disease Vaccines with Different Vegetable Oil Adjuvants in Goats under Field Conditions.
Desmettre Veterinary vaccines in the development of vaccination and vaccinology
RU2019120045A (ru) Вакцина для свиней
Ukhovskyi Study on immunogenic characteristics of experimental series of polyvalent vaccine against leptospirosis of animals" variant BOVIS" in laboratory conditions
AR084225A1 (es) Composiciones y metodos para vacunar ganado vacuno
Guimarães et al. Yellow fever vaccine, recombinant envelope protein (rYFE), plant derived, for active immunization: Pre-clinical studies in mice and monkey models
PH22018000416Y1 (en) Bivalent manilae and losbanos vaccine against locally prevalent leptospira serovars in the philippines